Navigation Links
MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of Single-Agent Activity in First-in-Human Clinical Study
Date:10/21/2013

of this single agent Phase I study are encouraging and further clinical development of ME-344 is warranted."

A copy of yesterday's poster presentation, entitled "ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human Phase I study," is now available at www.meipharma.com.

ME-344 was generally well tolerated at doses equal to or less than 10 mg/kg delivered on a weekly schedule for extended durations. Dose limiting toxicities were observed at both the 15 and 20 mg/kg dose levels, consisting primarily of Grade 3 peripheral neuropathy. Other medically significant adverse events observed in single patients included angina and QTc prolongation at the 10 mg/kg dose.

"We are encouraged by the results from this first-in-human study of ME-344," said Robert D. Mass, MD, Chief Medical Officer of MEI Pharma. "Not only did the trial show evidence of clinical activity, but the primary dose limiting toxicity was consistent with the proposed mechanism of action of ME-344, namely mitochondrial inhibition, suggesting on-target activity. Based on these findings, we are now actively preparing for a Phase Ib clinical trial of ME-344 in combination with Hycamtin® (topotecan) in small cell lung cancer and ovarian cancer, which we expect to initiate during the second quarter of 2014."

The Phase Ib trial will be designed to evaluate the safety and tolerability of ME-344 in combination with Hycamtin® in a total of 45 patients with either small cell lung cancer or ovarian cancer. Hycamtin® is a chemotherapy approved by the U.S. Food & Drug Administration for the treatment of small cell lung cancer and ovarian cancer, as well as cervical cancer.

About ME-344
ME-344 is MEI Pharma's isoflavone-derived mitochondrial inhibitor drug candidate. In preclinical studies, ME-344 has been shown to cause caspase-independent
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
2. PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry
3. ePharmaSolutions Wins Major Award for Life Sciences Industry Innovation
4. In Q1 Public Biopharmas Shift Fundraising into Overdrive
5. Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
6. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
7. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
8. MEI Pharmas Mitochondrial Inhibitor Drug Candidate ME-344 Named One of Top 10 Oncology Products for 2012
9. Among Newly Diagnosed Type 2 Diabetes Patients, DPP-IV Inhibitors are the Leading Oral Therapies After Standard Metformin and Sulfonylurea
10. MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
11. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014 ... ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... Medicine,s comprehensive genomic profiling to biopharmaceutical companies conducting clinical ... Under the terms of the collaboration, Foundation Medicine ... component of Foundation Medicine,s FoundationOne® assay at the WuXi ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... , , , , ... The Heart Failure Society of America,s (HFSA) 13th Annual ... in Boston. This three-day meeting -- a forum for heart failure specialists ... trends in research and new developments in the approach to treating patients ...
... , , , ... AMGN ) today announced the presentation of data highlighting ... reduction among women with postmenopausal osteoporosis. The data were presented at ... Research (ASBMR). , , "These data enhance our ...
Cached Medicine Technology:Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach 2Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 5Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 6Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 7Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 8Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 9
(Date:10/22/2014)... 22, 2014 With the Affordable Care Act ... by the American Institutes for Research (AIR) finds that three ... use health insurance, but 42 percent say they are not ... before signing up for coverage. , The AIR survey found ... percent able to calculate correctly how much they owe for ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world where ... it certainly can be difficult to choose the right weight ... by doing it the healthy way? Set aside the fads ... body, exercise regularly, and choose foods with the most nutritional ... need to exercise more and eat less. Despite the number ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... while working for NBC News in Liberia has cleared ... unit at Nebraska Medical Center in Omaha, where he had been ... A blood test confirmed by the U.S. Centers for Disease Control ... Providence, R.I., NBC News reported Tuesday night. "Recovering ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... ... but says there are still too many preventable automobile accidents. , ... New York, NY (PRWEB) April 23, 2010 -- The ... complacent to driving hazards as they hit the highway for a summer vacation road trip ...
... He Volunteered ... His Experience to Further the Search for a Cure and Better Treatments for PD. ... (PRWEB) -- “Deep Brain Diary: ... personal story about living with a neurological disease that afflicts over a million Americans. ...
... ... access to comprehensive statistics on global development challenges at data.worldbank.org. , ... Washington, DC (PRWEB) April 22, 2010 -- The World ... statistical databases and is challenging the global community to use the data to create ...
... The 25th Anniversary EAU Congress ended in Barcelona on ... support, interest and commitment shown by all participants, exhibitors ... the most memorable in the EAU,s congress history." ... Europe due to the vulcanic eruption in Iceland which ...
... by an Oregon Health & Science University Knight Cancer ... used to help identify physicians who might benefit ... A. Carney, Ph.D., OHSU School of Medicine professor of ... and associate director of Cancer Prevention, Control and Population ...
... ... , ... 27, 2010 -- Zane Benefits, Inc. announced today the release of a new ... insurance costs and the impact of health care reform. The program focuses on three new ...
Cached Medicine News:Health News:U.S. and New York Car Accident Deaths Continue Steady Decline 2Health News:Parkinson's Disease Patient's Story Goes Multimedia, Proceeds to Benefit PD Research 2Health News:Parkinson's Disease Patient's Story Goes Multimedia, Proceeds to Benefit PD Research 3Health News:Parkinson's Disease Patient's Story Goes Multimedia, Proceeds to Benefit PD Research 4Health News:World Bank Group Opens Data to All 2Health News:Memorable 25th Anniversary EAU Congress in Barcelona ends with awards 2Health News:Physicians who interpret mammograms may benefit from additional training 2Health News:Physicians who interpret mammograms may benefit from additional training 3Health News:Health Insurance Agents Work with Zane Benefits to Offer New Solutions amid Health Care Reform 2Health News:Health Insurance Agents Work with Zane Benefits to Offer New Solutions amid Health Care Reform 3
Coude Foley Catheters (Latex) 2-Way Amber...
Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
Medicine Products: